Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2011; 57(6): 3-14

Hydrogen sulfide inhibits Ca(2+)-induced mitochondrial permeability transition pore opening in adult and old rat heart

Strutyns'ka NA, Semenykhina OM, Chorna SV, Vavilova HL, Sahach VF

    Bogomoletz Institute of physiology NAS of Ukraine, Kyiv, Ukraine


In experiments in vivo and in vitro on the mitochondria iso­lated from adult and old rat hearts, we studied the effects of a donor of hydrogen sulfide (H2S), NaHS, and H2S biosynthesis substrate, L-cysteine, on the sensitivity of the mitochondrial permeability transition pore (mPTP) opening to its natural inductor, Ca2+. We found that NaHS (10-12 to 10-4 mol/l) influ­enced mitochondrial swelling in a concentration-dependent manner. It was also demonstrated that the addition of NaHS (10-12 to 10-8 mol/l) to the calcium-free medium resulted in moderate a swelling of mitochondria from both adult and old rat hearts. At 10-10 mol/l NaHS, the maximal values of the mitochondrial swelling observed in both adult and old hearts were 11 and 15 ,%, respectively. A specific inhibitor of KAT P -channels, 5-hydroxydecanoate (5-HD; 10-4 mol/l) decreased the mitochondrial swelling in the presence of NaHS (10-10 mol/ l), which can be indicative of the contribution of these channels to the calcium-independent conductance of the mitochondrial membranes in the rat hearts. The H2S donor NaHS used in physiological concentrations (10-6, 10-5 and 5 10-5 mol/l) exer­ted the inhibiting effect on the Ca2+-induced mPTP opening in adult hearts (corresponding values of such effect were 31, 76, and 77%, respectively), while in old hearts the protector ef­fect of NaHS was observed only at its concentration of 10-5 mol/l. Therefore, the donor of H2S used in the tested concentrations (10-12 to 10-4 mol/l) exerted ambiguous effect on the mitochondrial swelling: low concentrations of NaHS (10-12 to 10-8 mol/l) increased the mitochondrial swelling, while its physiological concentrations (10-6 to 5 10-5 mol/l) exerted the protective effect on Ca2+-induced mitochondrial swelling in adult and old hearts. Pre-incubation of isolated mitochon­dria with 5-HD (10-4 mol/l) resulted in a decrease in the protec­tive effect evoked by NaHS (10-5 mol/l) on Ca2+-induced mPTP opening, which is indicative of the possible involvement of mitochondrial KAT P -channels in the H2S-dependent inhibition of mPTP formation in both adult and old rat hearts. In experi­ments in vivo, single intraperitoneal injections of both NaHS (10-4 mol/kg) and L-cysteine ((10-3 mol/kg) resulted in a de­crease in the sensitivity of mPTP to its inductor Ca2+ in adult and old rat hearts. The action of L-cysteine, as compared with that of NaHS, was more effective in prevention of Ca2+-in-duced mitochondrial swelling. We observed a rise in Ca2+ concentration by one order of magnitude, which evoked the mitochondrial swelling in adult and old hearts. In experiments in vivo in which we used a specific blocker of cystathionine-g-lyase, propargylglycine (10-4 mol/kg) that is involved in the synthesis of H2S, we observed an increase in the sensitivity of mPTP opening in old hearts because of a decrease in the thresh­old Ca2+ concentration required for mitochondrial swelling by two orders of magnitude. We demonstrate the involvement of endogenous H2S in the control of mPTP formation in adult and old hearts. Our studies are indicative of the involvement of H2S in modulation of changes in the permeability of mitochon-drial membranes, which can be an important regulatory factor in the development of cardiovascular diseases.

Keywords: hydrogen sulfide, L-cysteine, mitochondrial permeability transition pore, heart, aging, rats


  1. Baskakov MB, Gusakova SV, Zheludeva AS, Smaglii LV, Kovalev IV, Vtorushina TA, Nosov DS, Eremenko KV, Medvedev MA ., Orlov SN Effect of hydrogen sulfide on the contractile activity of rat aortic smooth muscle cells . Bul. Siberia. medicine. 2010. N 6. p. 12-17.
  3. Moibenko AA, Dosenko VE, Parkhomenko AN Endogenous mechanisms of cardioprotection as a basis for pathogenetic therapy of heart disease. K .: Sciences. opinion, 2008. p. 206-251.
  5. Sahach VF, Rudyk OV, Vavilova HL, Kotsiuruba AV, Tkachenko IuP. [Melatonin recovers ischemic tolerance and decreases the sensitivity of mitochondrial permeability transition pore opening in the heart of aging rats].  Fiziol Zh. 2006. 52, N 3. p. 3-14.
  7. Sahach VF, Vavilova HL, Rudyk OV, Strutyns'ka NA. Release of unidentified substances of mitochondrial origin--evidence of mitochondrial permeability transition pore opening in the heart mitochondria of rats. Fiziol Zh. 2003. 49, N 5. p. 3-12.
  9. Sahach VF, Vavilova HL, Strutyns'ka NA, Rudyk OV. Aging-related increase of sensitivity of the mitochondrial permeability transition pore to inductors in the rat heart . Fiziol Zh. 2004. 50, N 2. p. 49-63.
  11. Shimanskaya TV, Dobrovolsky FV, Vavilova GL, Strutinskaya NA, Rudyk EV, Sagach VF NO-dependent modulation of the sensitivity of mitochondrial pore opening in ischemia . reperfusion of the isolated heart . Ross. physiol. . 2009. 95, N 1. p. 28-37.
  13. Cai W.J., Wang M.J., Moore P.K., Jin H.M., Yao T., Zhu Y.C. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation . Cardiovasc. Res. 2007. 76. P. 29-34. CrossRef PubMed
  15. Chang L., Geng B., Yu F., Zhao J., Jiang H., Du J, Tang C. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats . Amino Acids. 2008. 34. P. 573-585. CrossRef PubMed
  17. Elsey D.J., Fowkes R.C., Baxter G.F. Regulation of cardiovascular cell function by hydrogen sulphide (H S) . Cell. Biochem. Funct. 2010. 28. P. 95-106. CrossRef PubMed
  19. Halestrap A. What is the mitochondrial permeability transition pore?. Molecular and cell. Cardiol. 2009. 46. P.821-831. CrossRef PubMed
  21. Javadov S, Karmazyn M, Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. Pharmacol. Exp. Ther. 2009. 330(3) P. 670-678. CrossRef PubMed
  23. Ji Y, Pang Q.F., Xu G., Wang L., Wang J.K., Zeng YM. Exogenous hydrogen sulfide postconditioning protects isolated rat hearts against ischemia-reperfusion injury . Eur. J. Pharmacol. 2008. 587. P. 1-7. CrossRef PubMed
  25. Kapoor A., Thiemermann C. Hydrogen sulfide, neurogenic inflammation, and cardioprotection: a tale of rotten eggs and vanilloid receptors . Crit. Care Med. 2010. 38. P. 728-730. CrossRef PubMed
  27. Kimura H. Hydrogen sulfide: its production, release and functions . Amino Acids. 2010. 45. P. 56-61.
  29. Kubo S., Doe I., Kurokawa Y, Nishikawa H., Kawabata A. Direct inhibition of endothelial nitric oxide syn­thase by hydrogen sulfide: Contribution to dual modula- tion of vascular tension . Toxicology. 2007. 232. P. 138-146. CrossRef PubMed
  31. Lowicka E., Beltowski J. Hydrogen sulfide (H S) the third gas of interested for pharmacologists . Pharma-col. Rep. 2007. 59. P. 4-24.
  33. Li L., Hsu A., Moore P.K. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation-a tale of three gases. Pharmacol. Ther. 2009. 123. P. 386-400. CrossRef PubMed
  35. Li L., Rose P., Moore P.K. Hydrogen sulphide and cell signalling . Annu. Rev. Pharmacol. Toxicol. 2011. 51. P. 169-187. CrossRef PubMed
  37. Mancardi D., Penna C, Merlino A., Del Soldato P, Wink D.A., Pagliaro P. Physiological and pharmaco­logical featurers of the novel gasotransmitter : hydro­gen sulphide . Biochem. Biohys. Acta. 2009. 1787. P. 864-872. CrossRef PubMed PubMedCentral
  39. Rui W. Two's company, three's a crowd: can H S be the third endogenous gaseous transmitter . FASEB J. 2002. 16. P. 1792-1798. CrossRef PubMed
  41. Szabo C. Hydrogen sulphide and its therapeutic poten­tial . Nat. Rev. Drug Discov. 2007. 6. P. 917-935. CrossRef PubMed
  43. Sivarajah A., Collino M., Yasin M., Benetti E., Gallicchio M., Mazzon E, Cuzzocrea S, Fantozzi R, Thiemermann C. Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I. R . Shock. 2009. 31. P. 267-274. CrossRef PubMed
  45. Stipanuk M.H. Sulfur amino acid metabolism: path­ways for production and removal of homocysteine and cysteine . Annu. Rev. Nutr. 2004. 24. P. 539-577. CrossRef PubMed
  47. Tang G., Wu L., Liang W., Wang R. Direct stimulation of K-ATF channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells . Mol. Pharmacol. 2005. 68. P. 1757-1764. CrossRef PubMed
  49. Wagner F., Asfar P., Calzia E., Radermacher P., Szaby C. Bench-to-bedside review: Hydrogen sulfide the third gaseous transmitter: applications for critical care . Critical Care. 2009. 13. P. 213-222. CrossRef PubMed PubMedCentral
  51. Whiteman M., Moore P.K. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability . J. Cell. Mol. Med. 2009. 13. P. 488-507. CrossRef PubMed PubMedCentral
  53. Zhu Y.Z., Wang Z.J., Ho P., Loke YY, Zhu Y.C, Huang S.H., Tan C.S., Whiteman M., Lu J., Moore P.K. Hy­drogen sulfide and its possible roles in myocardial is­chemia in experimental rats . Appl. Physiol. 2007. 102. P. 261-268. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.